CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs
|
|
|
- Jordan Hicks
- 6 years ago
- Views:
Transcription
1 page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines used in HIV/AIDS treatment (antiretrovirals - ARVs) 2. Medicines used in malaria treatment 3. Medicines used in TB treatment 4. Anti-infectives (antibacterials, antiprotozoal, antifungal, antiviral, and antimycobacterial agents, anthelmintics) 5. Oral rehydration therapy 6. Other medicines (other antivirals, analgesics, antipyretics, palliative care agents, anti-epileptics, large volume parenterals, reproductive health, vitamins, cytotoxic agents, insulins) Entries highlighted in red correspond to new additions. Where a draft monograph has already been provided to the Secretariat for discussion, this is indicated by means of the symbol *.
2 page 2 1. Medicines used in HIV/AIDS treatment (antiretrovirals - ARVs) : Atazanavir : Emtricitabine oral solution Ritonavir capsules Ritonavir oral solution Stavudine powder for oral solution Zidovudine tablets Atazanavir capsules Fixed-dose combinations (FDC): Tenofovir and lamivudine tablets Tenofovir, efavirenz and lamivudine tablets Atazanavir and ritonavir tablets Lamivudine and abacavir tablets Lamivudine, abacavir and nevirapine tablets Lopinavir and ritonavir capsules Lopinavir and ritonavir oral solution Lamivudine and stavudine tablets Lamivudine, stavudine and nevirapine tablets, as available for: Lamivudine + Zidovudine + Efavirenz** ** to confirm with the Disease Programme
3 page 3 2. Medicines used in Malaria treatment Piperaquine phosphate Artesunate rectal capsules Fixed-dose combinations (FDC): Artemether and lumefantrine capsules Artemether and lumefantrine dispersible tablets Artesunate and amodiaquine tablets Dihydroartemisinin and piperaquine phosphate tablets Revision Artemisinin derivatives ( and dosage forms) (see
4 page 4 3. Medicines used in Tuberculosis (TB) treatment : Moxifloxacin p-aminosalicylic acid Terizidone : Moxifloxacin tablets/capsules Ethambutol oral liquid Pyrazinamide oral syrup p-aminosalicylic acid granules Ethionamide tablets/capsules Protionamide tablets Terizidone tablets/capsules
5 page 5 4. Anti-infectives (antibacterials, antiprotozoals, antifungals, antivirals, anthelminthics and antimycobacterial agents) Azithromycin Aciclovir Cefixime Rifabutin Ceftriaxone sodium Fluconazole Ivermectin Azithromycin capsules Azithromycin oral liquid Sulfadiazine tablets Clindamycin capsules Clindamycin injection Clindamycin oral liquid Aciclovir tablets Aciclovir powder for injection Aciclovir oral liquid Spectinomycin powder for injection Cefixime capsules Rifabutin capsules Albendazole chewable tablets Ceftriaxone injection Doxycycline dispersible tablets Fluconazole capsules Fluconazole injection Fluconazole oral solution/suspension Ivermectin tablets Pyrantel chewable tablets* Pyrantel oral solution* Pyrimethamine tablets Fixed-dose combinations (FDC): Sulfamethoxazole and trimethoprim injection Sulfamethoxazole and trimethoprim oral solution/suspension
6 page 6 5. Oral rehydration therapy Zinc acetate Zinc gluconate Paediatric zinc acetate tablets Paediatric zinc acetate oral solution Paediatric zinc gluconate oral solution Paediatric zinc gluconate tablets
7 page 7 6. Other medicines (other antivirals, analgesics, antipyretics, palliative care agents, anti-epileptics, LVPs 1, reproductive health, vitamins, cytotoxic agents, insulins) Morphine oral solution Paediatric Retinol oral solution Antiepileptics Carbamazepine oral liquid Carbamazepine chewable tablets Phenobarbital oral liquid Phenytoin oral liquid Phenytoin chewable tablets Valproic acid oral liquid Valproic acid crushable tablets Large volume parenterals Glucose intravenous infusion Sodium chloride intravenous infusion Sodium chloride and glucose intravenous infusion Reproductive health Mifepristone Misoprostol Norgestrel Mifepristone tablets Misoprostol tablets Norgestrel tablets Norethisterone tablets Norethisterone injection Note from Secretariat: used in co-blisters with Misoprostol tablets Ethinylestradiol + levonorgestrel tablets Medroxyprogesterone acetate (DMPA), depot injection 1 LVPs: Large Volume Parenterals
8 page 8 Cytotoxic medicines Bleomycin powder for injection Etoposide capsules Vinblastine powder for injection Vincristine powder for injection Calcium folinate tablets Calcium folinate injection Insulins Insulin, human Insulin, bovine Insulin, porcine Insulin preparations - General monograph Insulin injection (soluble) Insulin zinc suspension Isophane insulin injection Insulin zinc suspension (amorphous)** Insulin zinc suspension (crystalline)** Biphasic insulin injection** Biphasic isophane insulin injection ** Protamine zinc insulin injection** ** to confirm with the Disease Programme ***
1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017
To support national and global efforts to increase access to and the affordability of care and treatment of HIV/AIDS, hepatitis B and C, tuberculosis, malaria, neglected tropical diseases, influenza, diarrhoea
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016
To support national and global efforts to increase access to and the affordability of HIV/AIDS-related care and treatment together with UNICEF, UNAIDS and UNITAID, invite applicants for selected pharmaceutical
Invitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
5 Infections. To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and
5 Infections To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and Southend University Hospital, Antibiotic Guidelines Index 5.1 Antibacterial drugs
Chapter 5 ~ Infections
Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy
The International Pharmacopoeia - Overview
The International Pharmacopoeia - Overview Caroline Mendy - Technical Officer Quality Assurance and Safety: Medicines World Health Organization 1 The International Pharmacopoeia Ph. Int. Scope WHO Consultative
poor solubility and poor permeability unknown whether poor BA is due to poor solubility or antiglaucoma medicine for biowaiver Not eligible
Table 1 Substances on the WHO Model List of Essential Medicines (EML) Medicine a abacavir 200 mg high low 3 9.2.1.2 antiretroviral acetazolamide 250 mg low low (?) 4/2 antiglaucoma acetylsalicylic acid
Appendix 5: Hepatic impairment
Appendix 5: Hepatic impairment Liver disease may alter the response to drugs. However, the hepatic reserve appears to be large and liver disease has to be severe before important changes in drug metabolism
WHO Model List (revised April 2002)
Essential Medicines Explanatory Notes The complementary list presents essential medicines for priority diseases which are efficacious, safe and cost-effective but not necessarily affordable, or for which
Il programma dei farmaci essenziali dell OMS, la nuova lista marzo Suzanne Hill Department of Medicines Policy and Standards WHO
Il programma dei farmaci essenziali dell OMS, la nuova lista marzo 2007 Suzanne Hill Department of Medicines Policy and Standards WHO Essential medicines 30 years on Outline A review of 30 years of essential
Medicines recommended to prevent and manage the priority diseases at the community and health facility level
s recommended to prevent and manage the priority diseases at the community and health facility level Shamim Qazi Department of Child and Adolescent Health and Development Global Causes of Child Deaths
Prequalification Programme Bioequivalence Assessment Update. Dr. John Gordon
Prequalification Programme Bioequivalence Assessment Update Dr. John Gordon WHO Prequalification of Medicines Programme 3 rd Meeting with Manufacturers of FPPs and APIs Overview Review of commonly used
The Global Health Impact Index
The Global Health Impact Index Ranking Explanation Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine
Appendix 4: Renal impairment
Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some
Priority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
Compendium of Notified Ceiling Prices NLEM 2015
Compendium of Notified Ceiling Prices NLEM 2015 The Compendium of Notified Ceiling Prices of Scheduled Drugs as per NLEM 2015 has been brought out with the objective of disseminating information related
WEB ANNEX J. TABLE OF DRUG INTERACTIONS WITH ANTIRETROVIRAL DRUGS
WEB ANNEX J. TABLE OF DRUG INTERACTIONS WITH ANTIRETROVIRAL DRUGS In: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on
COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH
1 Abacavir Sulphate Antiretroviral - * - 2 Abiraterone Acetate Oncology - - - 3 Albendazole Anti-infective - - - 4 Albuterol Sulphate Respiratory - - 5 Alendronate Sodium Trihydrate Metabolic Disorder
EML 14 COMPLEMENTARY LIST
1. ANAESTHETICS 1.1 General anaesthetics and oxygen 1.2 Local anaesthetics ephedrine injection, 30mg (hydrochloride)/ml in 1-ml (see comment) 3mg/ml in 1mL, 10mL For reversal of hypotension from epidural
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
Appendix 1: Interactions
Appendix 1: Interactions Two or more drugs given at the same time may interact with each other. The interaction may be potentiation or antagonism of one drug by another, or occasionally some other. Drug
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing
Hospital Pharmaceuticals Review PTAC, Hospital Pharmaceuticals Subcommittee & Anti-Infective Subcommittee minutes for web publishing Infections therapeutic group PTAC and Subcommittee of PTAC minutes are
LIST OF ESSENTIAL MEDICINES OF RA
1. ANAESTHETICS 1) General anaesthetics and oxygen Inhalational medicines Nitrous Oxide Oxygen Halothane Isoflurane Injectable medicines Ketamine Propofol Thiopental Fentanyl 2) Local anaesthetics Bupivacaine
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS
SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets
Essential Medicines 15th edition (March 2007) WHO Model List (revised March 2007)
Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost effective medicines for priority conditions. Priority
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
WHO Model List of Essential Medicines
of Essential Medicines 17th list (March 2011) Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html
WHO Model List of Essential Medicines
of Essential Medicines 15 th list, March 2007 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html
Category and Product-level Procurement and Delivery Planning Guide
Category and Product-level Procurement and Delivery Planning Guide Indicative Lead Times 3 July 2018 This document lays out indicative lead-times for planning purposes for key health products for the Global
(To be Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
(To be Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
WHO Model List of Essential Medicines
of Essential Medicines 19th List (April 2015) (Amended June 2015) Status of this document This is a reprint of the text on the WHO Medicines website http://www.who.int/medicines/publications/essentialmedicines/en/
PROGRAM General Information
Association for Quality Assessment in TDM and Clinical Toxicology Section of the Dutch Foundation for Quality Assessment in Medical Laboratories PROGRAM 2016 General Information P.O. Box 43100, 2504 AC
WHO Model List of Essential Medicines
WHO Model List of Essential Medicines 20th List (March 2017) (Amended August 2017) Status of this document This is a reprint of the text on the WHO Medicines website http://www.who.int/medicines/publications/essentialmedicines/en/
Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013
istry of Health, Pharmacy Division STOCK STATUS REPORT AS AT NOVEMBER 1st 2013 Introduction The purpose of this report is to inform the istry of Health and all stakeholders of the stock levels in the country
Sources and Prices of Medicines for Children.
Sources and Prices of Medicines for Children. Consultation on Priority Essential Medicines for Child Survival 6th-7th September, 2010 Copenhagen, Denmark 1 Sources and Prices of Selected Medicines for
List of changes in Out-Patients Formulary
List of changes in Out-Patients Formulary Change in prescriber criteria Alpha Tocopheryl (Vitamin E) suspension 100mg/mL, tablets 50-150mg, tablets 670mg Atorvastatin tablets Bezafibrate tablets 400mg
REVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
Drug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
Inventory of paediatric therapeutic needs
12 December 2012 EMA/PDCO/287222/2012 Human Medicines Development and Evaluation Infectious diseases Agreed by PDCO November 2012 Adopted by PDCO for release for consultation 7 December 2012 Start of public
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
WHO Technical Report Series The Selection and Use of Essential Medicines
WHO Technical Report Series The Selection and Use of Essential Medicines Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2017 (including the 20th WHO Model List of Essential
List of Optimal Paediatric Formulations. Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013
List of Optimal Paediatric Formulations Marianne Gauval (CHAI) IAS-ILF Round table Geneva, Switzerland 26 November 2013 1 History of development of treatment options for children Adult tablets Syrups and
MEDICINES CATALOG NOVEMBER 2018 GLOBAL DRUG FACILITY (GDF)
NOVEMBER 2018 MEDICINES CATALOG GLOBAL DRUG FACILITY (GDF) Ensuring an uninterrupted supply of quality-assured, affordable tuberculosis (TB) medicines and diagnostics to the world. stoptb.org/gdf Stop
Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
Industry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
First DRAFT: WHO Model List of Essential Medicines for Children Explanatory notes
First DRAFT: WHO Model List of Essential Medicines for Children Explanatory notes 1. The aim of the list is to identify medicines, dosage forms and strengths that are essential for children aged 12 years
WHO Model List of Essential Medicines for Children Explanatory Notes
WHO Model List of Essential Medicines for Children Explanatory Notes This Model List is intended for use for children up to 12 years of age. 16 August 2007 The core list presents a list of minimum medicine
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary
At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors
GPRM - Global Price Reporting Mechanism November Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009
Transaction prices for Antiretroviral Medicines and HIV Diagnostics from 2008 to October 2009 A summary report from the Global Price Reporting Mechanism Contents Abbreviations. 5 Table 1 : of first-line
WHO Model List of Essential Medicines for Children
WHO Model List of Essential Medicines for Children 2nd List, March 2009 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html
WESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
Drug Development by Government Pharmaceutical Organization. Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand
Drug Development by Government Pharmaceutical Organization Dr. Rachaneekorn Jevprasesphant The Government Pharmaceutical Organization (GPO) Thailand 20August 2012 GPO s Profile GPO was established in 1966.
CEFACLOR Non Formulary 5.1 Antibacterial drugs->5.1.2 Cephalosporins, carbapenems, and other beta-lactams-> Cephalosporins
Report generated from BNF - Local Information provided by FormularyComplete (www.pharmpress.com). Accessed 31 07 2017 Title Formulary Status Section Amikacin Non Formulary 5.1 Antibacterial drugs->5.1.4
Appropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
Syria Essential Drugs List (EDL) Priority 2014
Syria Essential Drugs List (EDL) Priority 2014 1. ANAESTHETICS Quantities halothane Inhalation. 10.000 isoflurane Inhalation. 30.000 sevoflurane bottle (quick fill bottle adapter ) Inhalation. 10.000 nitrous
The Global Health Impact Index. Company Report
The Global Health Impact Index Company Report Reference Table Drug Abbreviation Drug Name 1. AL 1. Artemether-Lumefantrine 2. AS+AQ 2. Artesunate + Amodiaquine 3. AS+MQ 3. Artesunate + Mefloquine 4. AS+SP
Thank you for your request for information that has been processed under reference number
Corporate Development Contact us: dhft.foi@nhs.net Royal Derby Hospital Uttoxeter Road Derby DE22 3NE Tel: 01332 265500 Minicom: 01332 785566 www.derbyhospitals@nhs.uk Follow us on Twitter @DerbyHospitals
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
The International Pharmacopoeia
The International Pharmacopoeia Dr Sabine Kopp Quality Assurance and Safety: Medicines World Health Organization 2 The International Pharmacopoeia Int.Ph. 1. Introduction 2. Int. Ph. - historical overview
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
WHO Model List of Essential Medicines for Children
Essential Medicines for Children 5th List (April 2015) (Last amended June 2015) Status of this document This is a reprint of the text on the WHO Medicines website http://www.who.int/medicines/publications/essentialmedicines/en/
SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Darunavir Alvogen 400 mg, filmomhulde tabletten Darunavir Alvogen 800 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
PRODUCT LIST GENERAL - TABLETS
SR. NO. PRODUCT LIST GENERAL - TABLETS 1 Ciprofloxacin Tablets IP 500 mg 2 Ciprofloxacin And Tinidazole Tablets 3 Cefpodoxime Proxetil Tablets IP 4 Cefixime Dispersible Tablets 200 mg 5 Cefixime Dispersible
Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES
Toolkit on monitoring health systems strengthening MEDICAL PRODUCTS, VACCINES AND TECHNOLOGIES June 2008 Table of contents 1. Introduction... 2 2. Data sources... 2 Facility reporting systems...3 Key informant
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT PREZISTA 100 mg/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral suspension contains 100 mg of
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT PREZISTA 100 mg/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral suspension contains 100 mg of
THE INTERAGENCY EMERGENCY HEALTH KIT SVIZERA EUROPE BV
THE INTERAGENCY EMERGENCY HEALTH KIT SVIZERA EUROPE BV SVIZERA EUROPE 2019 Dear valued customer, In addition to all the products mentioned in the product list, Svizera Europe BV is specialized in making
Chapter 4 ~ Central nervous system
Chapter 4 ~ Central Nervous System: General Section 1 of 6 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics CHLORAL HYDRATE CLOMETHIAZOLE NITRAZEPAM TEMAZEPAM TRICLOFOS
The Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
Rajasthan Medical Services Corporation Limited, Jaipur
Rajasthan Medical Services Corporation Limited, Jaipur List of Drugs- Purchase order placed to successful Bidders Tendered on 05/07/2011 S.No. Name of Drug 1 Atropine Sulphate Injection 0.6 mg /ml (SC/IM/IV
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 37 1. NAME OF THE MEDICINAL PRODUCT Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg emtricitabine
Box 1. Recommendations unchanged from the first edition of the Guidelines (2006)
Executive summary Executive Summary Malaria case management remains a vital component of the malaria control strategies. This entails early diagnosis and prompt treatment with effective antimalarial medicines.
SUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 36 1. NAME OF THE MEDICINAL PRODUCT mg/300 mg Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg
Medicines Formulary BNF Section 4 Central Nervous System
Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
Combination Anti-malarial Therapy and WHO Recommendations
Prakaykaew Charunwatthana 2, and Sasithon Pukrittayakamee 1,2 1 Associate Fellow of the Royal Institute, Academy of Science 2 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
nevirapine, zidovudine and lamivudine
nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment
Ministry of Health, Pharmacy Division STOCK STATUS REPORT AS AT 1 JULY 2013
istry of Health, Pharmacy Division STOCK STATUS REPORT AS AT 1 JULY 2013 Introduction The purpose of this report is to inform the istry of Health and all stakeholders of the stock levels in the country
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Darunavir Krka 400 mg film-coated tablets Darunavir Krka 800 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
EML- ANTIRETROVIRALS INTERACTIONS TABLE
EML- ANTIRETROVIRALS INTERACTIONS TABLE February 2019 6 th Edition Medicines Information Centre Division of Clinical Pharmacology University of Cape Town Copyright 2019 National HIV & TB HCW Hotline, Medicines
Elizabeta Zisovska, Skopje, Republic of Macedonia
Elizabeta Zisovska, Skopje, Republic of Macedonia The comments are extracted and supported by the Drug register (for registered drugs in Republic of Macedonia) issued by the ministry of health, Republic
CHILDREN S MEDICINES IN UGANDA
Medicines for Children CHILDREN S MEDICINES IN UGANDA An investigation into availability and factors impacting access INTRODUCTION The continuous availability of affordable medicines for children is necessary
PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
Daclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
APRIL Key Findings: Overall. Key Findings: Availability
APRIL 2006 Key Findings: Overall o Medicines were more available in private pharmacies than in other sectors o Even for medicines on the Kenya Essential Drug List, 20 out of 28 of these had below 50% availability
reductions Untangling the web of price reductions: eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 1st December 2003
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
Supplier/ Manufacturer(s) Unit III, Survey No 51, Plot No IDA, Jeedimetla, Hyderabad, Telangana, Hetero labs limited
LIST OF DELISTED PRODUCTS Not eligible for procurement with the Global Fund resources 06th of April 2018 Delisted Mar-18 Ritonavir (RTV) 0 mg Tablet Unit Survey No 51, Plot No 22-1 IDA, Jeedimetla, Hyderabad,
Strategic Fund Medicine List / Lista de Medicamentos del Fondo Estratégico 1 Updated September
1 Updated September 10 2018 International Nonproprietary Name (INN) / Denominación Común Internacional (DCI) ANALGESICS Opioid analgesics Strength / Concentracion Presentation / Forma Farmacéutica Codeine
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
reductions Untangling the web of price reductions: 6th Edition eligibility pricecountries company price countries price
company price countries reductions pricecountries price eligibility reductions Untangling the web of price reductions: a pricing guide for the purchase of ARVs for developing countries 6th Edition 19th
Summary of the Report as of 1st February 2017
MINISTRY OF HEALTH PHARMACY DIVISION Stock Status Report 1st February 2017 A Publication of The Ministry of Health Uganda The purpose of this report is to inform the Ministry of Health and all stakeholders